Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Newly diagnosed Philadelphia chromosome positive Acute Lymphoblastic Leukemia (ALL)~* Age \>1 year and \< less than 18 years old~* Induction chemotherapy ≤ 14 days according to institutional standard of care~* Adequate liver, renal and cardiac function~Exclusion Criteria:~* Prior treatment with a Oncogene fusion protein (BCR-ABL) inhibitor~* Extramedullary involvement of the testicles~* Active systemic bacterial, fungal or viral infection~* Down syndrome

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Dasatinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).